Commons Health Select Committee ‘Brexit – Medicines, medical devices and substances of human origin’ inquiry – final session held
The third and final oral evidence session of the House of Commons Health Select Committee inquiry on ‘Brexit – Medicines, medical devices and substances of human origin’ was held on Tuesday 19 December 2017.
The Health Committee heard from patient and research charities, and representatives of the pharmaceutical industry about the impact Brexit poses for the full life science process from research and development through to clinical trials, manufacture, market launch and pharmacovigilance.
Evidence was heard from the following witnesses:
- Professor Alan Boyd, President of Faculty of Pharmaceutical Medicine, Academy of Medical Royal Colleges;
- Emma Greenwood, Director of Policy, Cancer Research UK;
- John Maingay, Director of Policy and Public Affairs, British Heart Foundation;
- Sir Hugh Taylor, Co-Chair, Brexit Health Alliance;
- Hugo Fry, UK General Manager, Sanofi;
- Warwick Smith, Director General, British Generic Manufacturers Association;
- Phil Thompson, President, Global Affairs, GlaxoSmithKline;
- John Wilkinson, Partner, Cooley LLP
MAP will publish the full transcript here once it becomes available.